Skip to main content

Table 1 Characteristics of the studies included in the analysis

From: Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

Study Publication year Population Follow-up (months) Design Dual lipid-lowering therapy Statin monotherapy
N Treatment Baseline LDL-C Baseline non-HDL-C N Treatment Baseline LDL-C Baseline non-HDL-C
HEAVEN [14] 2012 SAP 12 Single-blinded. RCT 42 Atorvastatin 80 mg/day + Ezetimibe 10 mg/day 119.9 143.1 47 Standard statin therapy 104.4 131.5
OCTIVUS [15] 2016 ACS 11.6 Double-blinded. RCT 39 Atorvastatin 80 mg/day + Ezetimibe 10 mg/day 142.9 162.1 41 Atorvastatin 80 mg/day + Placebo 158.3 177.6
ZEUS [16] 2014 ACS 6 Open label. Non RCT 50 Atorvastatin 20 mg/day + Ezetimibe 10 mg/day 116.2 137.5 45 Atorvastatin 20 mg/day 114.3 137.8
Hibi et al. [17] 2018 ACS 10 Open label. RCT 50 Pitavastatin 2 mg/day + Ezetimibe 10 mg/day 123.0 146.0 53 Pitavastatin 2 mg/day 126.0 150.0
PRECISE [18] 2015 ACS/SAP Basal LDL-C > 100 mg/dl 10.1 Single-blinded. RCT 100 Atorvastatina + Ezetimibe 10 mg/day 109.8 136.2 102 Atorvastatina 108.3 132.7
Masuda et al. [19] 2015 SAP Basal LDL-C > 100 mg/dl 6 Open label. RCT 21 Rosuvastatin 5 mg/day + Ezetimibe 10 mg/day 131.8 151.4 19 Rosuvastatin 5 mg/day 123.0 146.2
GLAGOV [20] 2016 SAP 19 Double-blinded. RCT 484 Statin + Evolucumab 420 mg M 92.6 119.4 484 Statin + Placebo 92.4 120.8
ODYSSEY-J [21] 2019 ACS. Basal LDL-C > 100 mg/dl 9 Open label. RCT 93 Statinb + Alirocumab 75/150 mg Q2W 97.9 124.1 89 Statinb 95.7 124.4
  1. ACS acute coronary syndrome, M one monthly, Q2W every 2 weeks, RCT randomized clinical trial, SAP stable angina pectoris
  2. aAtorvastatin was increased by titration with the usual dose range with a treatment goal of LDL-C < 70 mg/dl
  3. bStandard-of-care